Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure
Authors:
- 1 June 2018
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Cardiology
- Vol. 3 (6) , 498-505
Abstract
Importance Health-related quality of life (HRQL) of patients with heart failure is markedly reduced compared with that in patients with other chronic diseases, demonstrating substantial limitations in physical and social activities. In the Prospective Comparison of ARNI With an ACE-Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial, sacubitril/valsartan improved overall HRQL compared with enalapril, as determined by the Kansas City Cardiomyopathy Questionnaire (KCCQ). Objective To examine the effects of sacubitril/valsartan on physical and social activities. Design, Setting, and Participants The PARADIGM-HF trial was a randomized, double-blind, active treatment–controlled clinical trial performed from December 8, 2009, to March 31, 2014, in 8399 patients with New York Heart Association class II to IV disease and a left ventricular ejection fraction of 40% or less at 1043 centers in 38 countries. Data analysis was performed from August 1, 2017, to December 25, 2017. Interventions Sacubitril/valsartan, 200 mg twice daily, or enalapril, 10 mg twice daily. Main Outcomes and Measures Patients completed HRQL assessments using the KCCQ at randomization, 4-month, 8-month, and annual visits. The effect of sacubitril/valsartan on components of the physical and social limitation sections of the KCCQ at 8 months and longitudinally and related biomarkers and clinical outcomes were studied. Results At baseline, 7618 of 8399 patients (90.7%) (mean [SD] age, 64 [11] years; 5987 [78.6%] male and 1631 [21.4%] female) completed the initial KCCQ assessment. Patients reported the greatest limitations at baseline in jogging and sexual relationships. Patients receiving sacubitril/valsartan had significantly better adjusted change scores in most physical and social activities at 8 months and during 36 months compared with those receiving enalapril. The largest improvement over enalapril was in household chores (adjusted change score difference, 2.35; 95% CI, 1.19-3.50;P < .001) and sexual relationships (adjusted change score difference, 2.72; 95% CI, 0.97-4.46;P = .002); both persisted through 36 months (overall change score difference, 1.69 [95% CI, 0.78-2.60],P < .001; and 2.36 [95% CI, 1.01-3.71],P = .001, respectively). Conclusions and Relevance In patients with heart failure with reduced ejection fraction, sacubitril/valsartan significantly improved nearly all KCCQ physical and social activities compared with enalapril, with the largest responses in household chores and sexual relationships. In addition to reduced likelihood of cardiovascular death, all-cause mortality, and heart failure hospitalization, sacubitril/valsartan may improve limitations in common activities in these patients. Trial Registration clinicaltrials.gov Identifier:NCT01035255Keywords
This publication has 24 references indexed in Scilit:
- Dual Angiotensin Receptor and Neprilysin Inhibition as an Alternative to Angiotensin-Converting Enzyme Inhibition in Patients with Chronic Systolic Heart Failure: Rationale for and Design of the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure Trial (PARADIGM-HF)European Journal of Heart Failure, 2013
- Still at the Drawing BoardCirculation: Heart Failure, 2012
- Evaluation of the Functional Status Questionnaire in Heart Failure: A Sub-study of the Second Cardiac Insufficiency Bisoprolol Survival Study (CIBIS-II)Cardiovascular Drugs and Therapy, 2011
- Quality of life and symptoms of depression in advanced heart failure patients and their partnersCurrent Opinion in Supportive & Palliative Care, 2010
- UK‐414,495, a selective inhibitor of neutral endopeptidase, potentiates pelvic nerve‐stimulated increases in female genital blood flow in the anaesthetized rabbitBritish Journal of Pharmacology, 2010
- Sexual Concerns and Sexual Counseling in Heart FailureProgress in Cardiovascular Nursing, 2009
- Effects of Exercise Training on Health Status in Patients With Chronic Heart FailureJAMA, 2009
- The effect of beta‐blocker therapy on quality of life in heart failure patients: a systematic review and meta‐analysisPharmacoepidemiology and Drug Safety, 2006
- Monitoring clinical changes in patients with heart failure: A comparison of methodsAmerican Heart Journal, 2005
- Impact of heart failure and left ventricular systolic dysfunction on quality of life. A cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult populationEuropean Heart Journal, 2002